We leveraged this platform to developa novel therapeutic strategy localizing to macrophages with lipidnanoparticles specifically designed to safely deliver siRNA to phagocyticmacrophages in the tumor microenvironment and reduce SIRPα expression.These findings have the potential to influence advanced therapeuticstargeting metastatic OvCa in the clinic to improve therapy responseand ultimately patient survival. This evidence concerns the gene SIRPA and neoplasm.